




# THE BIOSIMILARS MARKETPLACE IS TAKING OFF: HERE'S WHY

Biosimilars have the potential to reduce costs and bring savings to patients, payers, employers, and the broader healthcare system.

## TAKE A CLOSER LOOK:


The U.S. regulatory environment is **evolving to support the uptake of biosimilars and the marketplace is taking off.**



As more biosimilars enter the marketplace, natural competition between products will **drive down prices and lower costs** across the system.




Between 2019 and 2020, there was a **65% jump in the number of approved biosimilars and a 157% increase in biosimilar products available to patients** with more launches on the way.<sup>1</sup>



In the U.S., the potential savings from lower-priced biosimilars is projected to reach between **\$40-250 billion by 2025.**<sup>2</sup>



The benefits of a competitive marketplace go beyond cost savings and have the potential to contribute to a more sustainable healthcare system through investments in innovative medicines and technologies and help provide for appropriate healthcare staffing levels.



## REFERENCES

1. Amgen. 2020 Biosimilar Trends Report. [https://www.amgenbiosimilars.com/-/media/Themes/Amgen/amgenbiosimilars-com/Amgenbiosimilars-com/pdf/USA-CBU-80853-2020-Amgen-Biosimilars-Trend-Report-v3\\_final.pdf](https://www.amgenbiosimilars.com/-/media/Themes/Amgen/amgenbiosimilars-com/Amgenbiosimilars-com/pdf/USA-CBU-80853-2020-Amgen-Biosimilars-Trend-Report-v3_final.pdf). Accessed September 2021.
2. Amgen. The Promise of Biosimilars. <https://www.amgenbiosimilars.com/-/media/Themes/Amgen/amgenbiosimilars-com/Amgenbiosimilars-com/pdf/v1/promise-of-biosimilars-fact-sheet.pdf>. Accessed September 2021.

